- Home
- KPRX vs VCIG Comparison
KPRX vs VCIG Comparison
Compare KPRX & VCIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- VCIG
- Stock Information
- Founded
- KPRX 1998
- VCIG 2013
- Country
- KPRX United States
- VCIG Malaysia
- Employees
- KPRX N/A
- VCIG N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- VCIG Diversified Commercial Services
- Sector
- KPRX Health Care
- VCIG Consumer Discretionary
- Exchange
- KPRX Nasdaq
- VCIG Nasdaq
- Market Cap
- KPRX 9.2M
- VCIG 7.5M
- IPO Year
- KPRX N/A
- VCIG 2023
- Fundamental
- Price
- KPRX $2.15
- VCIG $1.19
- Analyst Decision
- KPRX Strong Buy
- VCIG
- Analyst Count
- KPRX 1
- VCIG 0
- Target Price
- KPRX $10.00
- VCIG N/A
- AVG Volume (30 Days)
- KPRX 53.1K
- VCIG 9.0M
- Earning Date
- KPRX 11-07-2025
- VCIG 10-06-2025
- Dividend Yield
- KPRX N/A
- VCIG N/A
- EPS Growth
- KPRX N/A
- VCIG N/A
- EPS
- KPRX N/A
- VCIG 0.98
- Revenue
- KPRX N/A
- VCIG $32,903,041.00
- Revenue This Year
- KPRX N/A
- VCIG N/A
- Revenue Next Year
- KPRX N/A
- VCIG N/A
- P/E Ratio
- KPRX N/A
- VCIG $1.22
- Revenue Growth
- KPRX N/A
- VCIG 24.77
- 52 Week Low
- KPRX $2.05
- VCIG $0.91
- 52 Week High
- KPRX $4.18
- VCIG $4,644.01
- Technical
- Relative Strength Index (RSI)
- KPRX 33.03
- VCIG 35.50
- Support Level
- KPRX $2.26
- VCIG $0.93
- Resistance Level
- KPRX $2.39
- VCIG $2.18
- Average True Range (ATR)
- KPRX 0.14
- VCIG 0.42
- MACD
- KPRX -0.02
- VCIG 0.09
- Stochastic Oscillator
- KPRX 16.03
- VCIG 8.67
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About VCIG VCI Global Limited
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.